In Vitro Fertilization Test Market Size, Growth, Trends, Forecast 2021-2030
The global in vitro fertilization test market value reached over US$ 1.4 billion in 2020 and expected to grow at a noteworthy CAGR of 6.1% from 2020 to 2030.
The global in vitro fertilization test market size is expected to hit around US$ 2.8 billion by 2030. The surge in inclination toward delayed pregnancies, number of fertility clinics across the globe, and fertility tourism is anticipated to drive the global in vitro fertilization test market.
Solutions for Medically Complicated Patients, Simple Metrics Improve Clinical Numbers
The IVF procedure is potentially challenging in patients with pre-existing medical conditions. The IVF is a complex series of procedures involving ovarian stimulation, oocyte retrieval, and laboratory techniques to achieve maximal rates of fertilization, embryo development, and embryo transfer (ET). In order to ensure the faith of medically complicated patients, healthcare professionals are offering specific treatments to hypertension patients or patients with cardiovascular diseases. These include antihypertensive medications and regular cardiology consultation, respectively, to improve clinical outcomes in the in vitro fertilization test market.
Describing medical outcomes from in vitro fertilization test has been an evolving challenge throughout the world. This has led to the importance of three simple metrics that provide a transparent and highly accurate summary of IVF tests. These include the probability of having no embryo available to transfer, sustained implantation rate, and the number of supernumerary embryos cryopreserved during the cycle.
Preference for PGT-A to Improve Implantation Rates, Reduce Miscarriages
Based on claims of better live birth and reduced miscarriage rates, the technique of the preimplantation genetic testing for aneuploidy (PGT-A) in association with IVF has increasingly grown in the U.S. Companies in developing economies of South Asia are taking cues from such findings to improve their medical services in hospitals and fertility clinics.
PGT-A in a single trophectoderm biopsy at blastocyst stage reliably determines whether an embryo is euploid or chromosomal abnormal. PGT-A is gaining recognition in the in vitro fertilization test market for improving implantation rates and reducing miscarriages. This strategy has now become a routine add-on for IVF to determine whether human embryos are to be clinically utilized or disposed.
Preimplantation Genetic Testing to Dominate Global Market
In terms of test type, the global in vitro fertilization test market has been classified into sperm aneuploidy test, genetic compatibility test, preimplantation genetic testing, endometrial receptivity analysis, noninvasive prenatal testing, and others. The preimplantation genetic testing (PGD) segment is expected to dominate the global in vitro fertilization test market from 2021 to 2031. The usage of PGD for chromosomal aberrations, aneuploidy screening, gender selection, single gene disorder, HLA typing, and X-linked diseases has been increasing rapidly due to benefits associated with better pregnancy rate and birth of a healthy child. Aneuploidy screening using PGD has eased the method of detecting the risk of a syndrome caused due to variation in the number of chromosomes. This is expected to drive the segment during the forecast period.
Fertility Clinics to be Major End Users
Based on end user, the global in vitro fertilization test market has been divided into fertility clinics, hospitals, and others. The fertility clinics segment is likely to account for a significant share of the global in vitro fertilization test market by 2031. Rise in fertility tourism and insurance coverage and government initiatives in registration of fertility clinics to provide safe and high quality IVF treatments are likely to fuel the growth of the fertility clinics segment.
Regional Outlook
In terms of region, the global in vitro fertilization test market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa)
The report provides market size and forecast for each region and country/sub-region from 2017 to 2030. Compound annual growth rate (CAGR) of each of these regions and countries have also been provided for the forecast period from 2021 to 2030, considering 2020 as the base year. The in vitro fertilization test market study also covers the competitive scenario in these regions.
Overview
Key Players
The report provides profiles of leading players operating in the global in vitro fertilization test market. These include CooperSurgical, Inc., Esco Micro Pte Ltd., FUJIFILM Irvine Scientific, Hamilton Thorne, Inc., Vitrolife AB, IVFtech ApS, Nidacon International AB, Igenomix, Thermo Fisher Scientific, Cook, Genea Biomedx, FertiPro N.V, Kitazato Corporation, PerkinElmer, Inc., Natera, Takara Bio, Inc., iGLS, and CiceroDx.
Market: Segmentation
In this study, the years considered to estimate the market size of In vitro fertilization test are as follows:
· History Year: 2017-2020
· Base Year: 2020
· Forecast Year 2021 to 2030
Major Key Points Covered in Report:
Executive Summary: It includes key trends of the In vitro fertilization test market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the In vitro fertilization test market based on production and revenue.
Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.
Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the In vitro fertilization test market.
Market Segments: This part of the report discusses about product, application and other segments of the In vitro fertilization test market based on market share, CAGR, market size, and various other factors.
Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global In Vitro Fertilization Test Market
4. Market Overview
4.1. Introduction
4.1.1. Market Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global In Vitro Fertilization Test Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid /Long Term Impact)
5.3. Regulatory Scenario by Region/globally
5.4. Top 3 players operating in the market space
5.5. Key product/brand Analysis
6. Global In Vitro Fertilization Test Market Analysis and Forecast, by Test Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Test Type, 2017–2031
6.3.1. Sperm Aneuploidy Test
6.3.2. Genetic Compatibility Test
6.3.3. Preimplantation Genetic Testing
6.3.4. Endometrial Receptivity Analysis
6.3.5. Noninvasive Prenatal Testing
6.3.6. Others
6.4. Market Attractiveness Analysis, by Test Type
7. Global In Vitro Fertilization Test Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2031
7.3.1. Fertility Clinics
7.3.2. Hospitals
7.3.3. Others
7.4. Market Attractiveness Analysis, by End-user
8. Global In Vitro Fertilization Test Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Country/Region
9. North America In Vitro Fertilization Test Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Test Type, 2017–2031
9.2.1. Sperm Aneuploidy Test
9.2.2. Genetic Compatibility Test
9.2.3. Preimplantation Genetic Testing
9.2.4. Endometrial Receptivity Analysis
9.2.5. Noninvasive Prenatal Testing
9.2.6. Others
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Fertility Clinics
9.3.2. Hospitals
9.3.3. Others
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Test Type
9.5.2. By End-user
9.5.3. By Country
10. Europe In Vitro Fertilization Test Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Test Type, 2017–2031
10.2.1. Sperm Aneuploidy Test
10.2.2. Genetic Compatibility Test
10.2.3. Preimplantation Genetic Testing
10.2.4. Endometrial Receptivity Analysis
10.2.5. Noninvasive Prenatal Testing
10.2.6. Others
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Fertility Clinics
10.3.2. Hospitals
10.3.3. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Test Type
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific In Vitro Fertilization Test Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Test Type, 2017–2031
11.2.1. Sperm Aneuploidy Test
11.2.2. Genetic Compatibility Test
11.2.3. Preimplantation Genetic Testing
11.2.4. Endometrial Receptivity Analysis
11.2.5. Noninvasive Prenatal Testing
11.2.6. Others
11.3. Market Value Forecast, by End-user, 2017–2031
11.3.1. Fertility Clinics
11.3.2. Hospitals
11.3.3. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Test Type
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America In Vitro Fertilization Test Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Test Type, 2017–2031
12.2.1. Sperm Aneuploidy Test
12.2.2. Genetic Compatibility Test
12.2.3. Preimplantation Genetic Testing
12.2.4. Endometrial Receptivity Analysis
12.2.5. Noninvasive Prenatal Testing
12.2.6. Others
12.3. Market Value Forecast, by End-user, 2017–2031
12.3.1. Fertility Clinics
12.3.2. Hospitals
12.3.3. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Test Type
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa In Vitro Fertilization Test Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Test Type, 2017–2031
13.2.1. Sperm Aneuploidy Test
13.2.2. Genetic Compatibility Test
13.2.3. Preimplantation Genetic Testing
13.2.4. Endometrial Receptivity Analysis
13.2.5. Noninvasive Prenatal Testing
13.2.6. Others
13.3. Market Value Forecast, by End-user, 2017–2031
13.3.1. Fertility Clinics
13.3.2. Hospitals
13.3.3. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Test Type
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by Tier and Size of companies)
14.2. Market Share Analysis, by Company, 2020
14.3. Company Profiles
14.3.1. CooperSurgical, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Growth Strategies
14.3.1.3. SWOT Analysis
14.3.2. Esco Micro Pte Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Growth Strategies
14.3.2.3. SWOT Analysis
14.3.3. FUJIFILM Irvine Scientific
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Growth Strategies
14.3.3.3. SWOT Analysis
14.3.4. Hamilton Thorne, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Growth Strategies
14.3.4.3. SWOT Analysis
14.3.5. Vitrolife AB
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Growth Strategies
14.3.5.3. SWOT Analysis
14.3.6. IVFtech ApS
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Growth Strategies
14.3.6.3. SWOT Analysis
14.3.7. Nidacon International AB
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Growth Strategies
14.3.7.3. SWOT Analysis
14.3.8. Igenomix
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Growth Strategies
14.3.8.3. SWOT Analysis
14.3.9. Thermo Fisher Scientific
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Growth Strategies
14.3.9.3. SWOT Analysis
14.3.10. Cook
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Growth Strategies
14.3.10.3. SWOT Analysis
14.3.11. Genea Biomedx
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Growth Strategies
14.3.11.3. SWOT Analysis
14.3.12. FertiPro N.V
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Growth Strategies
14.3.12.3. SWOT Analysis
14.3.13. Kitazato Corporation
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Growth Strategies
14.3.13.3. SWOT Analysis
14.3.14. PerkinElmer, Inc.
14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.14.2. Growth Strategies
14.3.14.3. SWOT Analysis
14.3.15. Natera
14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.15.2. Growth Strategies
14.3.15.3. SWOT Analysis
14.3.16. Takara Bio, Inc.
14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.16.2. Growth Strategies
14.3.16.3. SWOT Analysis
14.3.17. iGLS
14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.17.2. Growth Strategies
14.3.17.3. SWOT Analysis
14.3.18. CiceroDx
14.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.18.2. Growth Strategies
14.3.18.3. SWOT Analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers